Eiger BioPharmaceuticals (EIGR) Plans Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Nasdaq, S&P muted as higher bond yields weigh
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Oil steadies as new sanctions interrupt easing tensions
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
August 17, 2016 4:02 PM EDTPALO ALTO, Calif., Aug. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Eiger intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares of common stock to be sold in the... More
